TD Asset Management’s Ascendis Pharma A/S ASND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $31.8M | Sell |
119,085
-98,907
| -45% | -$23.1M | 0.03% | 407 |
|
|
2026
Q1 | $49.9M | Sell |
217,992
-16,020
| -7% | -$3.59M | 0.04% | 315 |
|
|
2025
Q4 | $49.9M | Sell |
234,012
-62,334
| -21% | -$12.9M | 0.04% | 318 |
|
|
2025
Q3 | $58.9M | Buy |
296,346
+4,256
| +1% | +$794K | 0.05% | 288 |
|
|
2025
Q2 | $50.4M | Sell |
292,090
-51,300
| -15% | -$8.36M | 0.04% | 318 |
|
|
2025
Q1 | $53.5M | Buy |
343,390
+3,738
| +1% | +$534K | 0.05% | 309 |
|
|
2024
Q4 | $46.8M | Buy |
339,652
+86,528
| +34% | +$11.4M | 0.04% | 330 |
|
|
2024
Q3 | $36.6M | Buy |
253,124
+153,178
| +153% | +$20.7M | 0.03% | 363 |
|
|
2024
Q2 | $13.6M | Sell |
99,946
-136,924
| -58% | -$18.6M | 0.01% | 566 |
|
|
2024
Q1 | $35.8M | Sell |
236,870
-7,708
| -3% | -$1.1M | 0.03% | 355 |
|
|
2023
Q4 | $30.8M | Sell |
244,578
-22,782
| -9% | -$2.27M | 0.03% | 377 |
|
|
2023
Q3 | $25M | Buy |
267,360
+12,605
| +5% | +$1.18M | 0.03% | 388 |
|
|
2023
Q2 | $22.7M | Buy |
254,755
+18,561
| +8% | +$1.62M | 0.03% | 419 |
|
|
2023
Q1 | $25.3M | Buy |
236,194
+39,894
| +20% | +$4.56M | 0.03% | 397 |
|
|
2022
Q4 | $24M | Buy |
196,300
+64,700
| +49% | +$7.51M | 0.03% | 399 |
|
|
2022
Q3 | $13.5M | Buy |
131,600
+24,629
| +23% | +$2.34M | 0.02% | 505 |
|
|
2022
Q2 | $9.94M | Sell |
106,971
-6,820
| -6% | -$643K | 0.01% | 612 |
|
|
2022
Q1 | $13.4M | Buy |
113,791
+2,208
| +2% | +$256K | 0.01% | 586 |
|
|
2021
Q4 | $15M | Buy |
111,583
+20,948
| +23% | +$3.12M | 0.01% | 583 |
|
|
2021
Q3 | $14.4M | Buy |
90,635
+13,814
| +18% | +$1.89M | 0.02% | 560 |
|
|
2021
Q2 | $9.08M | Sell |
76,821
-28,174
| -27% | -$3.75M | 0.01% | 676 |
|
|
2021
Q1 | $13.5M | Sell |
104,995
-21,786
| -17% | -$3.31M | 0.02% | 561 |
|
|
2020
Q4 | $21.1M | Buy |
126,781
+11,016
| +10% | +$1.82M | 0.03% | 425 |
|
|
2020
Q3 | $17.9M | Sell |
115,765
-3,440
| -3% | -$494K | 0.02% | 417 |
|
|
2020
Q2 | $17.6M | Buy |
119,205
+4,801
| +4% | +$659K | 0.03% | 384 |
|
|
2020
Q1 | $12.9M | Sell |
114,404
-7,800
| -6% | -$1.01M | 0.02% | 423 |
|
|
2019
Q4 | $17M | Sell |
122,204
-5,000
| -4% | -$555K | 0.02% | 419 |
|
|
2019
Q3 | $12.3M | Buy |
127,204
+12,836
| +11% | +$1.43M | 0.02% | 473 |
|
|
2019
Q2 | $13.2M | Buy |
114,368
+27,000
| +31% | +$3.23M | 0.02% | 449 |
|
|
2019
Q1 | $10.3M | Buy |
87,368
+10,696
| +14% | +$937K | 0.02% | 513 |
|
|
2018
Q4 | $4.8M | Buy |
76,672
+10,436
| +16% | +$656K | 0.01% | 677 |
|
|
2018
Q3 | $4.69M | Buy |
66,236
+7,800
| +13% | +$537K | 0.01% | 747 |
|
|
2018
Q2 | $3.89M | Buy |
58,436
+6,300
| +12% | +$414K | 0.01% | 768 |
|
|
2018
Q1 | $3.41M | Buy |
52,136
+32,836
| +170% | +$1.85M | 0.01% | 763 |
|
|
2017
Q4 | $773K | Buy |
+19,300
| New | +$702K | ﹤0.01% | 1106 |
|
Other funds holding ASND
TD Asset Management's ASND Position: Q2 2026 in Review
TD Asset Management reduced its Ascendis Pharma A/S (ASND) stake by 45% in Q2 2026, selling an estimated $23.1M and leaving 119,085 shares worth $31.8M. The position accounts for 0.03% of the portfolio, ranked #407.
TD Asset Management first reported a position in ASND in Q4 2017 and has held it in 35 quarters since. The position peaked at $58.9M in Q3 2025. 208 funds tracked by Wall St. Rank hold ASND as of Q2 2026.
- TD Asset Management held 119,085 shares of Ascendis Pharma A/S worth $31.8M as of Q2 2026.
- TD Asset Management sold 98,907 Ascendis Pharma A/S shares in Q2 2026, an estimated $23.1M.
- Ascendis Pharma A/S made up 0.03% of TD Asset Management's portfolio in Q2 2026, its #407 holding.
- TD Asset Management first reported a position in Ascendis Pharma A/S in Q4 2017 and has held it in 35 quarters since.
- TD Asset Management's Ascendis Pharma A/S position peaked at $58.9M in Q3 2025.
- 208 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.
Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.